drugset / Trial / NCT03649880
Feasibility of FMISO in Brain Tumors
Phase 2
Recruiting
50 enrolled
OHSU Knight Cancer Institute
National Cancer Institute (NCI) · collabOregon Health and Science University · collabWeill Cornell University · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.
Timeline
- Start
- 2019-06-01
- Primary completion
- 2029-01-31
- Completion
- 2030-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-fluoromisonidazole | Diagnostic / imaging agent | — | Intravenous |